U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07663864) titled 'Luspatercept for CIA in AML' on June 06.
Brief Summary: This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Chemotherapy-inducing Anemia
Intervention:
DRUG: Luspatercept Injectable Product
First, enrolled patients were randomized to received rotezipeptide with a dosage of 1mg/kg at the day 1 versus day 10 post chemotherapy. Each groups were analyzed to ...